Hubei Jumpcan Pharmaceutical Co Ltd - Asset Resilience Ratio
Hubei Jumpcan Pharmaceutical Co Ltd (600566) has an Asset Resilience Ratio of 35.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 600566 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2024)
This chart shows how Hubei Jumpcan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Hubei Jumpcan Pharmaceutical Co Ltd (600566) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hubei Jumpcan Pharmaceutical Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥5.80 Billion | 35.1% |
| Total Liquid Assets | CN¥5.80 Billion | 35.10% |
Asset Resilience Insights
- Very High Liquidity: Hubei Jumpcan Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 35.10% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hubei Jumpcan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hubei Jumpcan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Hubei Jumpcan Pharmaceutical Co Ltd (2002–2024)
The table below shows the annual Asset Resilience Ratio data for Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 27.96% | CN¥5.16 Billion ≈ $755.21 Million |
CN¥18.46 Billion ≈ $2.70 Billion |
+10.44pp |
| 2023-12-31 | 17.52% | CN¥3.18 Billion ≈ $465.08 Million |
CN¥18.14 Billion ≈ $2.65 Billion |
-2.81pp |
| 2022-12-31 | 20.32% | CN¥3.04 Billion ≈ $445.51 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+6.51pp |
| 2021-12-31 | 13.81% | CN¥1.68 Billion ≈ $245.11 Million |
CN¥12.13 Billion ≈ $1.78 Billion |
+1.84pp |
| 2020-12-31 | 11.96% | CN¥1.26 Billion ≈ $184.08 Million |
CN¥10.52 Billion ≈ $1.54 Billion |
+9.77pp |
| 2019-12-31 | 2.19% | CN¥190.00 Million ≈ $27.80 Million |
CN¥8.66 Billion ≈ $1.27 Billion |
-1.50pp |
| 2018-12-31 | 3.69% | CN¥288.00 Million ≈ $42.14 Million |
CN¥7.80 Billion ≈ $1.14 Billion |
-6.39pp |
| 2017-12-31 | 10.09% | CN¥672.00 Million ≈ $98.33 Million |
CN¥6.66 Billion ≈ $974.94 Million |
+5.88pp |
| 2016-12-31 | 4.21% | CN¥210.00 Million ≈ $30.73 Million |
CN¥4.99 Billion ≈ $729.84 Million |
+0.58pp |
| 2015-12-31 | 3.63% | CN¥130.00 Million ≈ $19.02 Million |
CN¥3.59 Billion ≈ $524.66 Million |
-4.71pp |
| 2014-12-31 | 8.34% | CN¥280.00 Million ≈ $40.97 Million |
CN¥3.36 Billion ≈ $491.34 Million |
+8.29pp |
| 2006-12-31 | 0.05% | CN¥400.00K ≈ $58.53K |
CN¥786.51 Million ≈ $115.09 Million |
-5.83pp |
| 2003-12-31 | 5.88% | CN¥38.22 Million ≈ $5.59 Million |
CN¥650.39 Million ≈ $95.17 Million |
-1.38pp |
| 2002-12-31 | 7.26% | CN¥44.08 Million ≈ $6.45 Million |
CN¥607.22 Million ≈ $88.85 Million |
-- |
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovasc… Read more